期刊
CRITICAL CARE MEDICINE
卷 38, 期 -, 页码 S569-S573出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CCM.0b013e3181f1ff1d
关键词
pulmonary edema; acute respiratory distress syndrome; sepsis; acute respiratory failure
资金
- NHLBI NIH HHS [HL51854, HL093026, R01 HL051854, R37 HL051856, HL51856, R01 HL051856, K08 HL093026] Funding Source: Medline
- NICHD NIH HHS [K12 HD000850] Funding Source: Medline
Several experimental studies have suggested that mesenchymal stem cells may have value for the treatment of clinical disorders, including myocardial infarction, diabetes, acute renal failure, sepsis, and acute lung injury. In preclinical studies, mesenchymal stem cells have been effective in reducing lung injury from endotoxin, live bacteria, bleomycin, and hyperoxia. In some studies, the cultured medium from mesenchymal stem cells has been as effective as the mesenchymal stem cells themselves. Several paracrine mediators that can mediate the effect of mesenchymal stem cells have been identified, including interleukin-10, interleukin-1ra, keratinocyte growth factor, and prostaglandin E-2. Further preclinical studies are needed, as is planning for clinical trials for acute lung injury. (Crit Care Med 2010; 38[Suppl.]:S569-S573)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据